Tradestie Institutional Equity Comparison Engine

ZBIO vs CELC โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-16 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

ZBIO Overall Edge

ZBIO Captures Institutional Edge (2โ€“1 Pillars ยท 3โ€“3 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Zenas BioPharma, Inc. Common Stock (ZBIO) driven by superior Momentum & Technical, Options & Structure while CELC counters with relative strength in Growth & Margin. Fundamentally, ZBIO trades at N/M Forward P/E with -2747.5% operating margin (-100.0% YoY revenue) versus CELC at N/M Forward P/E and 0.0% operating margin (+0.0% YoY). In options structure, ZBIO sits in CONSOLIDATION (13th %ile IV; Dealer Gamma Walls on Pro) against CELC sits in BREAKDOWN (60th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner Tie
ZBIO N/M vs CELC N/M Fwd P/E
Growth & Margin Winner CELC
Op Margin -2747.5% vs 0.0% ยท YoY -100.0% vs +0.0%
Momentum & Technical Winner ZBIO
1Y -21.7% vs -29.6% ยท 52W Pos 46% vs 7%
Options & Structure Winner ZBIO
CONSOLIDATION (13th %ile IV) vs BREAKDOWN (60th %ile IV)
ZBIO NASDAQ
Zenas BioPharma, Inc. Common Stock
Pharmaceutical Preparations
$27.93
-0.29% 1D
Market Cap $1.9B
1M Return +12.44%
1Y Return -21.68%
Forward P/E N/M
Unified AI Score
49.4 / 100 HOLD
Tech 44.0 Fund 53.0 Flow 69.0 Mom 50.0
CELC NASDAQ
Celcuity Inc. Common Stock
Services-Medical Laboratories
$60.57
-5.9% 1D
Market Cap $3.1B
1M Return +7.05%
1Y Return -29.57%
Forward P/E N/M
Unified AI Score
39.7 / 100 SELL
Tech 25.0 Fund 43.0 Flow 59.0 Mom 64.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: ZBIO -21.68% CELC -29.57% Spread: +7.89 pp (ZBIO Lead)

Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant Revenue ($B) & Operating Margin (%)
ZBIO TTM Op. Margin: -2747.5% CELC TTM Op. Margin: 0.0%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on ZBIO vs CELC. Trailing 12-month operating profitability (ZBIO -2747.5% vs CELC 0.0%) and valuation multiples (ZBIO N/M vs CELC N/M Forward P/E) are benchmarked directly in Pillar 4 below.

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: ZBIO (3) vs CELC (3)
Institutional Metric ZBIO CELC Criterion Row Winner
Market Capitalization Scale $1.9B $3.1B Larger Scale CELC
Trailing P/E Ratio Valuation N/M N/M Lower Multiple Tie
Forward P/E Ratio Valuation N/M N/M Lower Multiple Tie
Revenue Growth (YoY) Growth -100.0% +0.0% Higher Growth CELC
Operating Margin (TTM) Profitability -2747.5% 0.0% Higher Margin CELC
Net Profit Margin Profitability 0.0% 0.0% Higher Margin Tie
Return on Equity (ROE) Capital Efficiency -265.1% -1192.9% Higher ROE ZBIO
52-Week Range Position Momentum 46% ($14โ€“$45) 7% ($54โ€“$151) Stronger Trend ZBIO
Beta / 30D Volatility Risk Regime 1.16ฮฒ ยท 59% Vol 1.28ฮฒ ยท 59% Vol Lower Realized Risk Tie
Unified Institutional Score Composite Signal 49.4 / 100 (HOLD) 39.7 / 100 (SELL) Higher Composite ZBIO

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full ZBIO vs CELC Buy Guide
ZBIO CONSOLIDATION
58d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 13th %ile
IV Regime Compressed (<25th %ile)
Live ZBIO Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
CELC BREAKDOWN
136d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 60th %ile
IV Regime Balanced (25thโ€“60th %ile)
Live CELC Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither ZBIO nor CELC registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.